Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label primary vaccination study of GSK134612 versus Mencevax ACWY in children aged 2 to 10 years
2012-000283-23Phase 3
- Sponsor
- GSK
- Start
- Apr 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in meningococcal disease comparing GSK134612 intramuscular with Mencevax ACWY subcutaneous (2 arms). Primary endpoint: Occurrence of any grade 3 systemic symptoms.
02
Drugs
meningococcal ACYW135 vaccinemeningococcal conjugate vaccine GSK 134612
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-000283-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000283-23.